MabVax Therapeutics Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MabVax Therapeutics Holdings, Inc.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
After manufacturing issues disrupted a Phase III study for its lead pipeline candidate, Pharnext believes it is back on track with new management, a fresh clinical trial and strong guidance from regulators. New CEO David Horn Solomon has blockbuster expectations for the company’s rare disease drug.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- MabVax Therapeutics, Inc.
- Telik, Inc.